Related Experiment Video
Updated: Sep 4, 2025
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
20.5K
WNT Medulloblastoma Limbo: How Low Can We Go?
Marc Remke1,2,3, Vijay Ramaswamy4,5
1Department of Pediatric Oncology, Hematology, and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Abstract:
Survival rates for average-risk medulloblastoma exceed 80%; however, long-term sequelae are substantial. A study from Mumbai, India evaluated the role of omission of craniospinal irradiation. Albeit unsuccessful, this study raises the crucial question of how low therapy can be safely de-escalated with the intent of improving quality of survival. See related article by Gupta et al., p. 4180.
